within Pharmacolibrary.Drugs.ATC.V;

model V09IB03
  extends Pharmacokinetic.Models.PK_2C(
    weight         = 70,
    F              = 1,
    Cl             = 1.6666666666666668e-07,
    adminDuration  = 600,
    adminMass      = 5 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0045,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,            
    Vdp             = 0.0012,
    k12             = 0.005,
    k21             = 0.005
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>V09IB03</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Indium (111In) antiovariumcarcinoma antibody is a radiopharmaceutical consisting of an antibody against human ovarian carcinoma cells, labeled with radioactive indium-111. It is used as a diagnostic imaging agent to localize ovarian carcinoma metastases or recurrences. It is not currently approved for routine clinical use, primarily used experimentally or in investigational settings.</p><h4>Pharmacokinetics</h4><p>No specific published pharmacokinetic parameters found in the literature for indium (111In) antiovariumcarcinoma antibody in humans. General estimates are reported for radiolabeled monoclonal antibodies in adult cancer patients.</p><h4>References</h4><ol><li><p>Gustavsson, T, et al., &amp; Syvänen, S (2024). Indium-111 radiolabelling of a brain-penetrant Aβ antibody for SPECT imaging. <i>Upsala journal of medical sciences</i> 129 –. DOI:<a href=\"https://doi.org/10.48101/ujms.v129.10585\">10.48101/ujms.v129.10585</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/38863725/\">https://pubmed.ncbi.nlm.nih.gov/38863725</a></p></li><li><p>Sandker, GGW, et al., &amp; Aarntzen, EHJG (2022). PD-L1 Antibody Pharmacokinetics and Tumor Targeting in Mouse Models for Infectious Diseases. <i>Frontiers in immunology</i> 13 837370–None. DOI:<a href=\"https://doi.org/10.3389/fimmu.2022.837370\">10.3389/fimmu.2022.837370</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/35359962/\">https://pubmed.ncbi.nlm.nih.gov/35359962</a></p></li><li><p>Koizumi, M, et al., &amp; Imamura, S (1988). Immunoscintigraphy and pharmacokinetics of indium-111-labeled ZME-018 monoclonal antibody in patients with malignant melanoma. <i>Japanese journal of cancer research : Gann</i> 79(8) 973–981. DOI:<a href=\"https://doi.org/10.1111/j.1349-7006.1988.tb00063.x\">10.1111/j.1349-7006.1988.tb00063.x</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/3141332/\">https://pubmed.ncbi.nlm.nih.gov/3141332</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end V09IB03;
